Peptide guide

Tirzepatide

A dual GIP/GLP-1 receptor agonist, FDA-approved as Mounjaro and Zepbound, studied for type-2 diabetes and weight loss.

Tirzepatide is the active ingredient in Mounjaro and Zepbound, two FDA-approved prescription drugs for type-2 diabetes and weight loss. It's a single peptide that switches on two gut-hormone receptors at once, GIP and GLP-1, which blunts appetite and slows the gut. The clinical evidence behind it is large and human, not animal. The catch is what's being sold gray-market: research-grade tirzepatide labeled "not for human consumption" is not the approved drug, isn't made to a sterile pharmaceutical standard, and isn't approved for anyone to inject. The drug works. The vial off a research-chemical site is a different question, and that's where the real risk lives.

By the Zapify Research team

Reviewed against 15 clinical & research sources · Updated June 2026 · Educational use only

Type: 39-aa peptideGIP/GLP-1 agonist
Route: Subcutaneousonce weekly
Typical dose: 2.5–15 mg/wktitrated in mg
Cycle: Titrate up slowly4-wk steps
Storage: Refrigerated2–8 °C
Status: Approved as a drugresearch-grade is not

What is Tirzepatide?

A 39-amino-acid peptide that activates both GIP and GLP-1 receptors; FDA-approved as Mounjaro and Zepbound, but research-grade powder is not that drug.

Tirzepatide is a peptide, a chain of 39 amino acids built in a lab from the human GIP hormone sequence, with a long fatty-acid tail bolted onto it. That tail lets the molecule grab onto albumin in your blood and ride along for days, which is why it's injected once a week instead of daily. It's the active ingredient in two brand-name prescription drugs: Mounjaro and Zepbound.

What makes it different from the earlier weight-loss peptides is that it works two gut-hormone receptors at the same time, GIP and GLP-1. Most of the drugs before it, including semaglutide, hit only GLP-1. Activating both appears to turn down appetite and slow the stomach harder than either one alone, which is the leading explanation for why the trial weight-loss numbers came in as high as they did.

Unlike most compounds covered here, tirzepatide has a deep human evidence base behind it. Tens of thousands of people have taken it in controlled trials. The approval isn't theoretical.

Read the approval carefully, because the nuance is the whole game. The finished drug, tirzepatide sold as Mounjaro (type-2 diabetes, approved 2022) or Zepbound (weight management, approved November 2023, and later obstructive sleep apnea), is FDA-approved and made under prescription-drug manufacturing rules. Research-grade tirzepatide, the powder sold online as a research chemical and labeled "not for human consumption," is not that product. It isn't FDA-approved, isn't made to a sterile fill standard, and isn't approved for self-administration by anyone. The molecule being approved as a drug says nothing about what's in an unregulated vial.

What is it studied for?

Backed by the large human SURPASS and SURMOUNT randomized trials enrolling tens of thousands, the basis for both FDA approvals.

The evidence here is the opposite of most peptides on this site: it's mostly human, and it's large. Tirzepatide ran through the SURPASS program for type-2 diabetes and the SURMOUNT program for weight, randomized controlled trials enrolling tens of thousands of people. That's the basis for both FDA approvals, and it's why the dosing below is anchored to real data rather than clinic folklore.

Evidence base, by subject

ExtensiveHuman controlled-trial data

MinorReliance on animal data

The research clusters in three areas:

Blood sugar (type-2 diabetes)The original SURPASS approval. Tirzepatide lowered A1C more than the GLP-1 drugs it was tested against, which is what earned Mounjaro.

Weight & obesityThe SURMOUNT trials. Reported average loss reached roughly 20% of body weight at the highest dose over about 72 weeks, the basis for Zepbound.

Sleep apnea & heartZepbound is also approved for obstructive sleep apnea in adults with obesity, and trials have reported cardiovascular benefit signals in diabetes.

The mechanism is unusually well characterized for a peptide. GIP and GLP-1 are incretin hormones your gut releases after a meal, and both receptors sit in brain regions that govern appetite. Tirzepatide switches both on at once, which slows stomach emptying, dampens hunger signaling, and improves how the body handles insulin. Exactly how much of the effect comes from the GIP arm versus the GLP-1 arm is still debated, but the overall pathway isn't a mystery the way it is for, say, BPC-157.

Why people use it

People want weight loss, diabetes control, or sleep-apnea relief, but going gray-market trades away the verified dose and sterile fill that make it safe.

Most people reaching for tirzepatide want one of a few outcomes. Unlike the recovery peptides, these aren't speculative, the drug has trial data behind each, but the reason someone tries it still isn't the same as a guarantee for their body:

Significant, sustained weight loss after diet and exercise alone haven't moved the number far enough.
Type-2 diabetes management, where the A1C reductions in trials outpaced the older GLP-1 options.
Obstructive sleep apnea tied to obesity, now a specific Zepbound indication.
Cost or access: people priced out of the brand drug, or unable to get a prescription, turning to gray-market vials to chase the same result.

The effect is real and human-tested, which is exactly why the sourcing question matters more here, not less. The pull toward a cheap research-chemical vial is strongest precisely because the brand version works and costs a fortune. What you give up going that route is the part that makes the drug safe: a verified dose, a sterile fill, and a prescriber watching for the things that go wrong. The molecule's track record doesn't transfer to a vial nobody tested.

How to reconstitute Tirzepatide

Brand pens come pre-mixed; research powder needs careful mixing, and since it's dosed in milligrams a small math slip is a large dose slip.

The brand pens, Mounjaro and Zepbound, arrive pre-mixed and ready to inject; there's nothing to reconstitute. Reconstitution only comes up with research-grade tirzepatide, which ships as a dry powder you'd have to mix yourself. The steps below describe how that powder is handled. They are not an endorsement of using it, the approved pen exists for a reason.

Step 1Start with powderWipe the rubber stopper with an alcohol swab.

Step 2Add bac. waterRun it slowly down the inside wall — never shake.

Step 3Draw your doseThe calculator gives the exact units to draw to.

Wipe the rubber stopper with an alcohol swab first, every time.
Use bacteriostatic water, not plain sterile water and not saline. The trace of benzyl alcohol in it holds back bacteria, which matters because you'll be drawing from the same vial across several weeks.
Add the water slowly, running it down the inside glass wall. Don't blast it straight onto the powder.
Don't shake it. Swirl gently and let it dissolve on its own. Shaking foams the solution and can damage the peptide.

A common gray-market setup is a 10 mg vial mixed with 1 mL of bacteriostatic water, giving 10 mg/mL. On a U-100 insulin syringe, 25 units then draws 2.5 mg, the typical starting dose. The water doesn't change how much peptide is in the vial; it only sets the concentration, which decides how many units you draw. The trap with tirzepatide specifically is that it's dosed in milligrams, so a small slip in the math is a large slip in dose. That's the math the calculator exists to remove.

Calculate your exact Tirzepatide reconstitution →

Dose & units

The approved schedule titrates from 2.5 mg up to a 15 mg weekly maximum in 2.5 mg steps held at least four weeks each.

The brand drugs have an FDA-approved dosing schedule, set by a prescriber for your situation. There is no approved self-dosing protocol for research-grade tirzepatide. The numbers below describe the approved titration as a reference, not a recipe to run on your own. Tirzepatide is dosed in milligrams, not the micrograms used for peptides like BPC-157, so don't carry dosing intuition over from anything else. Decide what goes into your body with a licensed provider.

Typical range

The approved range runs from a 2.5 mg starting dose up to a 15 mg weekly maximum, all injected under the skin once a week. The 2.5 mg start is a tolerability step, not a treatment dose; it exists to let your gut adjust before the dose that actually does the work.

Titration

Dose rises in 2.5 mg increments, and each step holds for at least four weeks before the next: 2.5 mg for weeks 1–4, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg as the ceiling. You don't jump straight to a high dose because the gastrointestinal side effects, nausea above all, are worst right after each increase. Climbing slowly is how the drug stays tolerable. There's no medal for starting high.

Cycling

Tirzepatide isn't cycled like a recovery peptide. It's a maintenance medication: you titrate up to an effective dose and stay there, and the benefit tends to fade if you stop. That's a clinical decision a prescriber makes, not a fixed on/off schedule.

Start2.5 mg · 4 wks

Titrate up+2.5 mg every 4 wks

Maintaineffective dose

For the exact mark to draw to on an insulin syringe from a reconstituted vial, don't eyeball it. The calculator turns vial size, water, and target dose into the precise number of units, which matters more with a milligram-dosed drug than almost anything else here.

Get your exact units →

Storage

Brand pens last up to 21 days at room temperature; reconstituted research vials go in the fridge and are used within roughly 2–4 weeks.

Sealed & dryBrand pens keep refrigerated until use; sealed research-grade powder stays stable for months and tolerates shipping.

ReconstitutedRefrigerate reconstituted vials and use within roughly 2–4 weeks; don't freeze, keep out of light, discard if cloudy or discolored.

Research-grade powder behaves more like the other peptides before it's mixed: a sealed, dry vial is stable for months and tolerates shipping. Once you reconstitute it, the clock starts and the vial belongs in the fridge, used within roughly 2–4 weeks. That window is about contamination, not potency, the peptide itself often holds longer, but the preservative in bacteriostatic water only keeps a multi-draw vial clean for so long.

Don't freeze a reconstituted or liquid vial, keep it out of direct light, write the mix date on the label, and throw it out if the solution ever turns cloudy or discolored, whatever the date says.

Side effects & safety

Side effects are mostly gastrointestinal, but it carries an FDA boxed warning for thyroid C-cell tumors and is contraindicated with medullary thyroid carcinoma.

Because tirzepatide has real human trials behind it, its side-effect profile is well documented rather than guessed at. The most common effects are gastrointestinal, and they're worst in the first weeks and right after each dose increase, which is the whole reason for slow titration.

Most common: nausea, diarrhea, vomiting, constipation, and reduced appetite. Nausea was reported in roughly a quarter to a third of users across the obesity trials, varying by dose, and usually eases as the dose stabilizes.
Injection-site reactions, fatigue, and a feeling of fullness or burping.
Less common but serious: pancreatitis (severe abdominal pain radiating to the back), gallbladder problems, and dehydration from heavy vomiting or diarrhea.

Tirzepatide carries the FDA's boxed warning, its most serious label warning, for thyroid C-cell tumors. It caused thyroid tumors in rats; whether that translates to humans is unknown, but it's contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Don't use it if that's you. Talk to a doctor before starting if you've had pancreatitis or gallbladder disease, are pregnant or breastfeeding, or take other glucose-lowering medication. Severe, persistent abdominal pain warrants prompt medical attention.

If you compete, this is worth tracking: as of January 2026, WADA added markers of tirzepatide and semaglutide to its Monitoring Program, watching for misuse both in- and out-of-competition. That isn't a ban yet, monitored substances aren't prohibited, but it signals these drugs are on anti-doping's radar and the status could tighten. Check the current list before a competition.

And once you're past the drug's own profile, the biggest risk shifts to the vial itself. The approved pen is a known quantity. A research-chemical vial isn't, and the real question becomes whether it actually contains tirzepatide, at the strength on the label, free of contamination. That comes down to where you buy it.

How to vet a source

Gray-market vials turn up underdosed or non-sterile, so demand a batch-specific third-party COA and match its lot number to your vial.

Tirzepatide sits in an unusual spot. The brand drug is so expensive and so in-demand that a large gray market grew up selling research-grade powder around it, and after the FDA declared the shortage resolved in late 2024, routine compounding was largely shut off, pushing more buyers toward unregulated vials. Independently tested gray-market product turns up underdosed, impure, or non-sterile often enough that where you buy matters more than almost anything else. The one document that separates a real seller from a gamble is a certificate of analysis: a third-party lab's report on what's actually in the vial.

A real COA shows

An identity test (usually mass spectrometry) confirming the peptide is what the label says.
A purity figure from HPLC, typically 98% or higher.
A lot or batch number that matches the number printed on your vial.
A named, independent accredited lab and a recent test date.

Walk away if

There’s no COA, or it’s a generic image with no lot number.
The “certificate” comes from the seller instead of a third-party lab.
The lot number doesn’t match your vial, or there isn’t one at all.
It’s a flat image you can’t trace back to the lab that issued it.

That's the standard worth holding any seller to, ours included. Ask for the batch-specific COA before you buy, match the lot number to your vial, and don't accept a screenshot in place of a traceable report. With a milligram-dosed drug carrying a boxed warning, the verified-dose question isn't a formality.

See the Zapify compound catalog →

Common questions about Tirzepatide

Is tirzepatide FDA-approved?

The finished drug is, the research-grade powder isn't, and the distinction is everything. Tirzepatide is approved as Mounjaro for type-2 diabetes (2022) and as Zepbound for weight management (November 2023) and obstructive sleep apnea (2024), both prescription products made under pharmaceutical manufacturing rules. Tirzepatide sold online as a research chemical, labeled "not for human consumption," is not that approved product, isn't made to a sterile standard, and isn't approved for anyone to inject.

How is tirzepatide different from semaglutide (Ozempic / Wegovy)?

Semaglutide activates one receptor, GLP-1. Tirzepatide activates two, GIP and GLP-1, with a single molecule. In head-to-head diabetes trials tirzepatide produced larger A1C and weight reductions, which is the main reason it draws so much interest. Both are weekly subcutaneous injections, both are dosed by slow titration, and both were added to WADA's 2026 Monitoring Program (watched, not yet banned).

Why do you start at 2.5 mg and not jump to a higher dose?

The 2.5 mg starting dose is a tolerability step, not a treatment dose. The gastrointestinal side effects, nausea especially, are worst right after each increase, so the dose climbs in 2.5 mg increments with at least four weeks at each step up to a 15 mg ceiling. Jumping doses mostly buys you worse nausea, not faster results.

Is tirzepatide dosed in milligrams or micrograms?

Milligrams. Reported doses run 2.5–15 mg per week. That's a thousand-fold different unit from the micrograms used for peptides like BPC-157, so don't carry dosing intuition between them. The milligram scale is also why the reconstitution math is easy to get badly wrong, a small error in units is a large error in dose.

Can I still get tirzepatide from a compounding pharmacy?

Mostly not, as a routine option. The FDA declared the tirzepatide shortage resolved in December 2024, and the enforcement grace periods for 503A and 503B compounding expired in February and March 2025. Compounded tirzepatide is now limited to narrow circumstances, which is part of why the gray market for research-grade vials grew. The right path for the actual drug is a prescription for the brand product through a licensed provider.

References

This page is for research and educational purposes only. It is not medical advice or a recommendation to use any compound. The dose ranges shown are reported by clinics and research literature, not validated medical standards, and Tirzepatide is not FDA-approved. Talk to a licensed medical provider about anything you put in your body.